NeuroEM Therapeutics Accepted into StartUp Health's Alzheimer's Moonshot Community

NeuroEM Therapeutics®, a clinical-stage biotechnology company focusing on Transcranial Electromagnetic Treatment leveraging Radio Frequencies (TEMT-RF) against Alzheimer's disease, has joined StartUp Health's Alzheimer's Moonshot Community™. This membership allows NeuroEM access to a network of organizations dedicated to finding a cure for Alzheimer's.

The Alzheimer's Moonshot initiative, supported by Gates Ventures and ADDF's Diagnostic Accelerator, was established to accelerate innovation in Alzheimer's care. NeuroEM’s CEO, Chuck Papageorgiou, expressed gratitude for joining the community, emphasizing the collaboration with top innovators and influential backers like ADDF and Gates Ventures.

NeuroEM’s mission aligns with the community's goals of advancing research in early detection and treatment of Alzheimer's. Their TEMT-RF technology aims to combat cognitive decline by using a pioneering head cap that patients can wear at home. This device attacks toxic protein oligomers in the brain and balances the immune system, showing significant promise in studies.